CoChat

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

Open access

The DOI matches its Crossref record; 69 of the 74 references it cites were found in a registry or an index.

Abstract

Non-alcoholic steatohepatitis (NASH) is becoming a leading cause of cirrhosis with the burden of NASH-related complications projected to increase massively over the coming years. Several molecules with different mechanisms of action are currently in development to treat NASH, although reported efficacy to date has been limited. Given the complexity of the pathophysiology of NASH, it will take the engagement of several targets and pathways to improve the results of pharmacological intervention, which provides a rationale for combination therapies in the treatment of NASH. As the field is moving towards combination therapy, this article reviews the rationale for such combination therapies to treat NASH based on the current therapeutic landscape as well as the advantages and limitations of this approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2019-319104

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Percentage of patients with resolution of non-alcoholic steatohepatitis (NASH) defined as ballooning 0 and inflammation 0–1, without worsening fibrosis in placebo and intervention arms of randomised clinical trials showing an effect. (B) Percentage of patients with more than one-stage improvement in fibrosis without worsening of NASH in placebo and intervention arms of randomised clinical trials showing an effect. The references are provided in the text, the data for the obeticholic acid phase 3 are based on study by Sanyal et al. 2
Figure 1 (A) Percentage of patients with resolution of non-alcoholic steatohepatitis (NASH) defined as ballooning 0 and inflammation 0–1, without worsening fibrosis in placebo and intervention arms of randomised clinical trials showing an effect. (B) Percentage of patients with more than one-stage improvement in fibrosis without worsening of NASH in placebo and intervention arms of randomised clinical trials showing an effect. The references are provided in the text, the data for the obeticholic acid phase 3 are based on study by Sanyal et al. 2CC BY-NC · PubMed Central
Figure 2 Rationale for combination therapy to treat non-alcoholic steatohepatitis (NASH). Drugs with different mechanisms of action targeting hepatic steatosis, inflammation and fibrosis could be combined. Ideally, such combinations should be safe and have positive effects beyond the liver such as weight loss, cardiovascular protection, insulin sensitisation and lipid reduction.
Figure 2 Rationale for combination therapy to treat non-alcoholic steatohepatitis (NASH). Drugs with different mechanisms of action targeting hepatic steatosis, inflammation and fibrosis could be combined. Ideally, such combinations should be safe and have positive effects beyond the liver such as weight loss, cardiovascular protection, insulin sensitisation and lipid reduction.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 69 references

Research works printed but not linked: 3

  1. Amin, 2019, PF-05221304 (PF’1304), a liver-targeted acetyl-CoA carboxylase inhibitor (ACCI), in afults with non-alcoholic fatty liver disease demonstrates robust reductions in liver fat and ALT - phase 2a, dose ranging study, Hepatology, 70 Suppl, 21
  2. 2019, Effects of cotadutide (MEDI0382) on biomarkers of non-alcoholic steatohepatitis in overweight or obese subjects with type 2 diabetes mellitus: a 26-week analysis of a randomized phase 2B study, Hepatology, 70, 24A
  3. Press release: Gilead Announces Topline results from phase 2 atlas study in patients with bridging fibrosis (F3) and compensated cirrhosis (F4) due to nonalcoholic steatohepatitis (NASH) 2019.

Cited by

See all 193

Metadata

Authors
Dufour, J.-F., Caussy, C., & Loomba, R.
Affiliations
  • University of Bern (CH)
  • University of California San Diego (US)
Corresponding author
Dufour, Jean-François
Venue
Gut
Publisher
BMJ
Published
2020-05-07
Volume
69
Issue
10
Pages
1877-1884
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3020979243
Cited by
193
References
74
Citations by year
2026: 11 · 2025: 23 · 2024: 31 · 2023: 36 · 2022: 43 · 2021: 38 · 2020: 11
FWCI
4.67
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • HighWire Press Open Archive (submittedVersion)
  • Open Access CRIS of the University of Bern
Funders
  • U.S. Department of Defense (5UL1TR001442, CA170674P2)
  • National Institutes of Health (UL1TR001442)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK106419, P30DK120515)
  • National Institute of Environmental Health Sciences (P42ES010337)
  • National Center for Advancing Translational Sciences
  • DOD Peer Reviewed Cancer Research Program
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
nonalcoholic steatohepatitis, combination therapy, NASH treatment, liver cirrhosis, therapeutic target, pathophysiology, drug development, pharmacological interventions
MeSH terms
Clinical Trials as Topic, Drug Therapy, Combination, Humans, Treatment Outcome, Medication Therapy Management, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. https://app.cochat.ai/papers/10.1136/gutjnl-2019-319104
The paper
Dufour, J.-F., Caussy, C., & Loomba, R. (2020). Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut. https://doi.org/10.1136/gutjnl-2019-319104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.